This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ASM journals
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Baudner, B. C.
Right arrow Articles by Del Giudice, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Baudner, B. C.
Right arrow Articles by Del Giudice, G.

 Previous Article  |  Next Article 

Infection and Immunity, September 2002, p. 4785-4790, Vol. 70, No. 9
0019-9567/02/$04.00+0     DOI: 10.1128/IAI.70.9.4785-4790.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Enhancement of Protective Efficacy following Intranasal Immunization with Vaccine Plus a Nontoxic LTK63 Mutant Delivered with Nanoparticles

B. C. Baudner,1 O. Balland,2 M. M. Giuliani,1 P. Von Hoegen,2 R. Rappuoli,1 D. Betbeder,2 and G. Del Giudice1*

IRIS Research Center, Chiron SpA, 53100 Siena, Italy,1 Biovector Therapeutics, Chemin du Chêne Vert, 31676 Labège, France2

Received 25 February 2002/ Returned for modification 3 May 2002/ Accepted 13 June 2002

Most vaccines are still given parenterally. Mucosal vaccination would offer different advantages over parenteral immunization, including blocking of the pathogens at the portal of entry. In this paper, nontoxic Escherichia coli heat-labile enterotoxin (LT) mutants and Supramolecular Biovector systems (SMBV) were evaluated in mice as mucosal adjuvants and delivery systems, respectively, for intranasal immunization with the conjugated group C meningococcal vaccine. The conjugated vaccine formulated together with the LT mutants and the SMBV induced very high titers of serum and mucosal antibodies specific for the group C meningococcal polysaccharide. This vaccination strategy also induced high titers of antibodies with bactericidal activity, which is known to correlate with efficacy. Importantly, the mucosal vaccination, but not the conventional parenteral vaccination, induced bactericidal antibodies at the mucosal level. These data strongly support the feasibility of development of intranasal vaccines with an enhanced protective efficacy against meningococci and possibly against other encapsulated bacteria.

* Corresponding author. Mailing address: IRIS Research Center, Chiron SpA, Via Fiorentina 1, 53100 Siena, Italy. Phone: 39-0577-243261. Fax: 39-0577-243564. E-mail: giuseppe_del_giudice{at}chiron.it.

Editor: J. T. Barbieri

Infection and Immunity, September 2002, p. 4785-4790, Vol. 70, No. 9
0019-9567/02/$04.00+0     DOI: 10.1128/IAI.70.9.4785-4790.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Negri, D. R. M., Pinto, D., Vendetti, S., Patrizio, M., Sanchez, M., Riccomi, A., Ruggiero, P., Del Giudice, G., De Magistris, M. T. (2009). Cholera Toxin and Escherichia coli Heat-Labile Enterotoxin, but Not Their Nontoxic Counterparts, Improve the Antigen-Presenting Cell Function of Human B Lymphocytes. Infect. Immun. 77: 1924-1935 [Abstract] [Full Text]  
  • Tritto, E., Muzzi, A., Pesce, I., Monaci, E., Nuti, S., Galli, G., Wack, A., Rappuoli, R., Hussell, T., De Gregorio, E. (2007). The Acquired Immune Response to the Mucosal Adjuvant LTK63 Imprints the Mouse Lung with a Protective Signature. J. Immunol. 179: 5346-5357 [Abstract] [Full Text]  
  • Stephenson, I., Zambon, M. C., Rudin, A., Colegate, A., Podda, A., Bugarini, R., del Giudice, G., Minutello, A., Bonnington, S., Holmgren, J., Mills, K. H. G., Nicholson, K. G. (2006). Phase I Evaluation of Intranasal Trivalent Inactivated Influenza Vaccine with Nontoxigenic Escherichia coli Enterotoxin and Novel Biovector as Mucosal Adjuvants, Using Adult Volunteers. J. Virol. 80: 4962-4970 [Abstract] [Full Text]  
  • Bowe, F., Lavelle, E. C., McNeela, E. A., Hale, C., Clare, S., Arico, B., Giuliani, M. M., Rae, A., Huett, A., Rappuoli, R., Dougan, G., Mills, K. H. G. (2004). Mucosal Vaccination against Serogroup B Meningococci: Induction of Bactericidal Antibodies and Cellular Immunity following Intranasal Immunization with NadA of Neisseria meningitidis and Mutants of Escherichia coli Heat-Labile Enterotoxin. Infect. Immun. 72: 4052-4060 [Abstract] [Full Text]  
  • Richter, M. Y., Jakobsen, H., Birgisdottir, A., Haeuw, J.-F., Power, U. F., Del Giudice, G., Bartoloni, A., Jonsdottir, I. (2004). Immunization of Female Mice with Glycoconjugates Protects Their Offspring against Encapsulated Bacteria. Infect. Immun. 72: 187-195 [Abstract] [Full Text]  


Copyright © 2010 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»